Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Dynavax Technologies Corporation    DVAX

DYNAVAX TECHNOLOGIES CORPORATION

(DVAX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

DYNAVAX TECHNOLOGIES CORP : Results of Operations and Financial Condition (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 04:21pm EDT

Item 2.02. Results of Operations and Financial Condition

Dynavax Technologies Corporation ("Dynavax") announced in its presentation at the J.P. Morgan 37th Annual Healthcare Conference in San Francisco, California that it expects sales of HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the fiscal quarter ended December 31, 2018 to be no less than $3.7 million. This amount is preliminary, unaudited, subject to change upon completion of our audit, and may differ from what will be reflected in our audited consolidated financial statements as of and for the quarter and year ended December 31, 2018. Additional information and disclosures would be required for a more complete understanding of our financial position and results of operations as of December 31, 2018.

The information with respect to item 2.02 in this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DYNAVAX TECHNOLOGIES CORPO
06/05DYNAVAX TECHNOLOGIES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
06/05DYNAVAX TECHNOLOGIES : Change in Directors or Principal Officers (form 8-K/A)
AQ
06/03DYNAVAX TECHNOLOGIES : to Present at the William Blair & Co. Annual Growth Stock..
PU
06/03Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference ..
GL
06/03Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-..
GL
06/01Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembro..
GL
05/31DYNAVAX TECHNOLOGIES CORP : Submission of Matters to a Vote of Security Holders ..
AQ
05/24DYNAVAX TECHNOLOGIES : Announces Strategic Restructuring to Focus on its Vaccine..
AQ
05/23DYNAVAX TECHNOLOGIES CORP : Costs Associated with Exit or Disposal Activities, C..
AQ
05/23DYNAVAX TECHNOLOGIES : Announces Strategic Restructuring to Focus on its Vaccine..
AQ
More news
Financials ($)
Sales 2019 45,4 M
EBIT 2019 -128 M
Net income 2019 -134 M
Finance 2019 36,0 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 5,16x
Capi. / Sales 2020 3,21x
Capitalization 270 M
Chart DYNAVAX TECHNOLOGIES CORPORATION
Duration : Period :
Dynavax Technologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DYNAVAX TECHNOLOGIES CORPO
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 30,2 $
Spread / Average Target 628%
EPS Revisions
Managers
NameTitle
Eddie J. Gray Chief Executive Officer & Director
Arnold Lewis Oronsky Chairman
David F. Novack Senior Vice President-Operations & Quality
Michael S. Ostrach Chief Financial & Business Officer, Senior VP
Robert L. Coffman Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
DYNAVAX TECHNOLOGIES CORPORATION-55.19%304
GILEAD SCIENCES7.27%80 909
VERTEX PHARMACEUTICALS4.87%42 680
REGENERON PHARMACEUTICALS-16.74%32 744
GENMAB11.33%10 857
SAREPTA THERAPEUTICS INC16.44%8 523